p53 modulates acquired resistance to EGFR inhibitors and radiation. - Wikidata - wikimedia - TriplyDB

p53 modulates acquired resistance to EGFR inhibitors and radiation.

p53 modulates acquired resistance to EGFR inhibitors and radiation.

http://www.wikidata.org/entity/Q39446317

about

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.The role of p53 in cancer drug resistance and targeted chemotherapy Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity.Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.Targeted Knockdown of the Kinetochore Protein D40/Knl-1 Inhibits Human Cancer in a p53 Status-Independent Manner.Tumour suppressor genes in chemotherapeutic drug response.p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.A bead-based western for high-throughput cellular signal transduction analyses.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer Integr(at)in(g) EGFR therapy in HNSCC Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth.Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway.RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.Addressing intra-tumoral heterogeneity and therapy resistance.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance.Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.

P2860

Q27852569-A37622B8-F678-4A95-8D3A-3F87CD924364 Q27853024-33CE4EC7-7B1E-4067-BEF3-E163C57602EB Q28072553-F3B1BA64-3930-4A9F-9122-1355834E76B1 Q33725229-0FCD755F-78AD-4EB4-81C1-9601B63FB52B Q33798605-900A6149-2CC8-46FC-820A-23CD1A846E6F Q34958488-61627228-8D56-4D14-A193-8FCA71C844B0 Q35012485-F2C06E9B-9318-498D-A6FA-12947ED46DB7 Q35016510-E42CE997-3CF0-4BF2-87BC-578B68A48A78 Q35099489-99E21115-A163-4DC8-A591-53C4B80A466F Q35901968-ADDB352C-6289-4FC4-9265-92EC3739996A Q36035358-64145E5E-2617-4E82-8A07-53EDA6A305E7 Q36083098-D13DDFB1-8A17-4D4C-9600-A4E286DA67CB Q36085351-B0E4B7FF-4D55-4BC7-8F94-7B987F7A0224 Q36092864-E9D657F8-B842-4EF6-A1FD-38C1058CDC8E Q36141854-13FE89B2-94BE-491D-AB34-8570129167E6 Q36306149-CEA3D1B6-FEB4-40B6-9841-CAF8E7DA6D2A Q36403862-DB384021-A158-4F23-9D03-22B4B793ED91 Q36584173-2A4D8D22-29D7-4FF1-8595-28585CD37934 Q36670915-75DAE392-F4E0-4C2C-A6E5-7F829A9F0255 Q36693836-3499067C-E90F-40B9-ADEE-4515BE156F0E Q37027400-DB60258B-01FD-4D42-91A7-FB50A389F271 Q37392703-1E662CF3-76F1-4175-99A8-FEF745BB3D45 Q37639112-C83D8538-D6A8-43E0-83DA-F8150BC0E935 Q38118934-64788DE5-F318-4CB1-8974-84CB4A2363DE Q38715267-AACC9100-72EF-434C-9D4C-5C33F5E38AF5 Q38756835-0348A2E2-0E01-48EF-8080-50AE8D5DDB73 Q38823179-9111035F-46DD-4E39-B021-592BC7A7B10E Q38869420-F82FE962-4D97-4459-9C4F-1D7D2274D731 Q38911597-A95D44AD-D0EF-4B32-90CF-4653729DE38A Q41561392-EF8316AC-C226-4DC4-A1EE-50951C58CDB5 Q41816821-A43971FF-0566-45A3-A054-C079AF1C52CD Q47117539-42664C17-1078-4A0A-B03D-0D7E4A64CB40 Q51101297-7010DFA5-29F2-4240-A9C4-831B10FFCF7E Q55025386-1154DF91-E037-46F0-AF2D-520EF6B5075F Q55457466-39BD910F-7C45-4ABA-B004-4F5558FD0475

P2860

p53 modulates acquired resistance to EGFR inhibitors and radiation.

http://www.wikidata.org/entity/Q39446317

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@en

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@nl

type

label

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@en

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@nl

prefLabel

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@en

p53 modulates acquired resistance to EGFR inhibitors and radiation.

@nl

P1433

Q39446317-7686E3B9-FFE2-4238-89FE-D407E53DA8F5

P1476

Q39446317-C3D88F7F-B288-48BF-87FE-63AC219AAB20

P2093

Q39446317-59764D1F-4BB4-4690-A453-A6D1756F933F

Q39446317-8968DF05-00E7-4CF8-A1CE-2D929FA92695

Q39446317-AD1DFBAE-37B6-4BCC-A6B4-715C22280935

Q39446317-C54BC404-59D7-46BC-93D0-2882FC1BF010

Q39446317-D978B52E-F0FB-4C1F-B479-2AA075CC72D1

P2860

Q39446317-066C5BFD-B5A3-41F5-995B-F2A8802121A6

Q39446317-096DB85B-0EB8-4C21-B1E8-607AF496193D

Q39446317-1950FEC4-2CB0-4DEF-AA37-83F29B7B690E

Q39446317-26ED3BAD-5376-4650-9EF0-C5959555B7AF

Q39446317-2D614A42-A210-43DF-9EEA-332C25CE750A

Q39446317-30B66308-3DE8-481E-BDFA-ED3468F80021

Q39446317-31F62401-E4AC-436B-A136-874457323E64

Q39446317-3301F933-17F4-461B-8243-8C55D5E1854B

Q39446317-3FFDB0BE-0FF4-4202-AB82-6BA928AF89AC

Q39446317-455CB853-9DB0-4A7D-9F54-C6073F845650

P304

Q39446317-90AD2CDC-463D-42A4-AAA8-A66A2DDEECFF

P31

Q39446317-F759A2B8-007F-41BF-AB20-F06C71FE0AE4

P356

Q39446317-F6374C73-7111-4482-A06D-2F3D37DC4BEA

P407

Q39446317-A85C79D8-7CF0-49D0-A518-831BE050A7E1

P433

Q39446317-63195BF0-652D-4AD1-8A11-E002705EEFF1

P478

Q39446317-DB51D50A-DA6A-48A6-B65C-443E75DE2FC3

P50

Q39446317-BA0FCBDC-E586-4769-B36D-43625EB2D0CA

P577

Q39446317-F2E424E0-6D4A-4F0A-B1BD-77735CC1AA44

P698

Q39446317-46FE5DA2-A740-49B5-824A-1134FFE1CF6F

P932

Q39446317-ACE76CDB-D9CB-40B7-AD9A-33E2F6ECF93B

P356

0008-5472.CAN-11-0128

P1433

Cancer Research

P1476

p53 modulates acquired resistance to EGFR inhibitors and radiation

@en

P2093

Chunrong Li

http://www.w3.org/2001/XMLSchema#string

Deric L Wheeler

http://www.w3.org/2001/XMLSchema#string

Eric A Armstrong

http://www.w3.org/2001/XMLSchema#string

Paul M Harari

http://www.w3.org/2001/XMLSchema#string

Shyhmin Huang

http://www.w3.org/2001/XMLSchema#string

P2860

The first 30 years of p53: growing ever more complex

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

EGFR antagonists in cancer treatment

Restoration of p53 function leads to tumour regression in vivo

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

TP53 mutations in human cancers: origins, consequences, and clinical use

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

P304

7071-7079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-0128

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Sergi Benavente

P577

2011-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22068033

http://www.w3.org/2001/XMLSchema#string

P932

3229180

http://www.w3.org/2001/XMLSchema#string